Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL

Javier Pinilla-Ibarz, MD, PhD
Published: Tuesday, Jun 13, 2017



Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses the outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) and how ibrutinib (Imbruvica) targets these patients.

High-risk patients with CLL has always been a challenge for patients being treated with chemoimmunotherapy, as they present with molecular features such as TP53, 17p, 11q, or heavy-chained unmutated IGHV. These patients don't respond very well to standard chemoimmunotherapy regimens.

However, with the introduction of new BCR inhibitors such as ibrutinib and idelalisib (Zydelig), patients are able to be successfully treated and can experience an improvement in progression-free survival.


Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses the outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) and how ibrutinib (Imbruvica) targets these patients.

High-risk patients with CLL has always been a challenge for patients being treated with chemoimmunotherapy, as they present with molecular features such as TP53, 17p, 11q, or heavy-chained unmutated IGHV. These patients don't respond very well to standard chemoimmunotherapy regimens.

However, with the introduction of new BCR inhibitors such as ibrutinib and idelalisib (Zydelig), patients are able to be successfully treated and can experience an improvement in progression-free survival.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x